dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021; dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021 at 9:09 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 02-Mar-2021 at 9:09 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021/vial stored at cooler storage during high-pace COVID-19 vaccination clinic at the time of the excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion during 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 69.93 years. No concomitant medications were reported. Batch number 014M20A underwent temperature excursion on 02-Mar-2021 with temperature 32 degrees Fahrenheit at 11:00 AM and at 12:00 PM with temperature 33 degrees Fahrenheit. The vial was initially moved to the fridge on 24-Feb-2021 and proposed beyond use date was 26-Mar-2021. Product moved to clinic on 02-Mar-2021. 16 vials were sent to clinic. On the date of administration from cooler 1, at 09:00 A.M., the temperature recorded was 27 degree Fahrenheit and at 10:00 A.M., the temperature recorded was 29 degree Fahrenheit, at 11:00 A.M., the temperature recorded was 32 degree Fahrenheit and at 12:00 P.M, the temperature recorded was 33 degree Fahrenheit, at 1:00 PM, the temperature recorded was 36 degree Fahrenheit, at 2:00 PM the temperature recorded was 35 degree Fahrenheit that has been reached by the vial.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).